PRP for Tennis Elbow: What the Randomized Evidence Says About Short Versus Long Term

The randomized evidence on platelet-rich plasma for tennis elbow tells a two-part story. In the first weeks a corticosteroid injection relieves pain faster, but by six months and beyond PRP tends to pull ahead on pain and function. The wrinkle is that PRP preparations differ so much that trial results do not always transfer from one clinic, or one study, to the next. So the honest answer to "does PRP work" is: it depends on when you measure and what exactly was injected.

What tennis elbow actually is

Lateral epicondylitis, the everyday name for pain on the outer elbow that flares with gripping, is not truly an inflammatory condition despite the "-itis" ending. Tissue studies describe a failed healing response in the common extensor tendon, with disorganized collagen and abnormal small blood vessels rather than the swarm of inflammatory cells you would see in an acute injury. That distinction matters for treatment logic. A corticosteroid calms inflammation and can quiet pain quickly, but if the underlying problem is a stalled repair process, an anti-inflammatory effect may not fix the tendon itself. Platelet-rich plasma, which concentrates a patient's own platelets and the growth factors they release, is proposed to nudge that repair process forward. Whether it delivers on that promise is an empirical question, and the trials give a more textured answer than either enthusiasts or skeptics usually admit.

The corticosteroid-versus-PRP crossover

The clearest synthesis comes from a 2024 systematic review and meta-analysis in the American Journal of Sports Medicine by Xu and colleagues, which pooled 11 randomized controlled trials covering 730 patients who received either PRP or corticosteroid injections. The pattern the authors found is best described as a crossover. In the short term, defined as under two months, corticosteroid injections produced significantly better pain relief and function on both the visual analog scale and the Disabilities of the Arm, Shoulder and Hand score. At six months and beyond, the direction reversed: PRP was associated with better long-term functional improvement and better sustained pain relief.

That crossover is the single most useful thing to carry away. A patient who judges either treatment at the wrong time can reach the opposite conclusion. Someone assessing corticosteroid at eight weeks sees a winner; someone assessing the same injection at eight months may see benefit that has faded, since several trials of steroid for tennis elbow show early relief followed by higher recurrence later. PRP shows the mirror image, with an underwhelming start and a stronger finish. Meta-analytic pooling like this also carries its own limits: combining trials that used different preparations and outcome scales can smooth over real differences between studies, so the summary direction is more trustworthy than any single pooled number.

What one well-run trial showed

The pattern is easier to trust when a large individual trial echoes it. A double-blind, multicenter randomized controlled trial by Mishra and colleagues, published in the same journal, enrolled 230 patients with chronic tennis elbow and compared leukocyte-rich PRP plus tendon needling against a needling control. At 12 weeks the two groups were statistically indistinguishable, with roughly 55 percent pain improvement in the PRP arm versus 47 percent in the control arm, a gap that did not reach significance. By 24 weeks the separation had grown: about 71 percent pain improvement with PRP against 56 percent for control, now a statistically significant difference, with a higher proportion of PRP patients meeting the trial's success threshold. No significant complications were reported in either group.

Two features of that trial deserve emphasis. First, the control was not a sugar pill but active needling, so the PRP benefit sits on top of a procedure that itself may stimulate healing, which makes the added effect more credible and also more modest. Second, the story only appears if you wait. A reader who stopped at the 12-week readout would conclude PRP had failed. That is exactly the timing trap the meta-analysis warns about.

Why the preparations are not interchangeable

Here is where confidence has to soften. "PRP" is not one product. Preparations vary in platelet concentration, in whether they are leukocyte-rich or leukocyte-poor, in activation method, and in how many injections are given, and these differences plausibly change the biology. A 2022 systematic review and meta-analysis examining leukocyte concentration in lateral epicondylitis found that leukocyte-rich PRP was associated with better long-term visual analog scale scores and success rates than control, while leukocyte-poor PRP showed no clear separation from control. That is a meaningful signal, though the underlying trials are heterogeneous and it should be read as a hypothesis about which preparation matters rather than a settled recipe.

The practical consequence is that a trial testing one formulation does not automatically vouch for the syringe offered down the street. When PRP is marketed, the specific preparation, concentration, and injection protocol are often unstated, yet those are precisely the variables the evidence suggests can move the result. Reading a positive headline as an endorsement of all PRP is a mistake the data do not support.

How to read the evidence

Put together, the randomized picture is coherent without being triumphant. Corticosteroid buys fast relief that tends not to last; PRP asks for patience and, in the better trials and pooled analyses, rewards it at six months and beyond; and the size of that reward depends on a preparation that is far from standardized. None of this settles what any individual should do, because trial averages describe populations, not people, and the comparators, costs, and out-of-pocket burden differ sharply between a steroid injection and a blood-derived one. This article is educational and is not medical advice; decisions about injections for tennis elbow belong in a conversation with a qualified clinician who knows your history. The most defensible takeaway is narrow but real: judge these injections by the right clock, and ask what is actually in the syringe.